PEG2000-C-DMG

• UNSPSC Description:

  PEG2000-C-DMG, a pegylated lipid, can be used for the preparation of Onpattro. Onpattro, a hepatically directed investigational RNAi therapeutic agent, harnesses this process to reduce the production of mutant and wild-type transthyretin by targeting the 3′ untranslated region of transthyretin mRNA[1][2].

• Target Antigen:

  Liposome

• Type:

  Oligonucleotides

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/peg2000-c-dmg.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CCCCCCCCCCCCCC(O[C@@H](COC(NCCCOCCOC)=O)COC(CCCCCCCCCCCCC)=O)=O.[45]

• Molecular Weight:

  2610.29

• References & Citations:

  [1]Garber K. Alnylam launches era of RNAi drugs. Nat Biotechnol. 2018;36(9):777-778. |[2]Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11-21.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported